Hepamerz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-Ornithine l-Aspartate) ## Overview Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is used in the treatment of latent and manifest hepatic encephalopathy, particularly in patients with liver cirrhosis. It is believed to work by promoting the detoxification of ammonia in the liver and brain. ## Primary Indications * Latent and manifest hepatic encephalopathy associated with hyperammonemia in patients with liver cirrhosis. ## Adult Dosing * **Acute Treatment:** 3-6 g intravenously (IV) every 8 hours. Higher doses up to 12 g IV per day may be used in severe cases under medical supervision. * **Maintenance Therapy:** 9-18 g orally per day, divided into 3 doses. ## Pediatric Dosing * Dosing for pediatric patients is not well-established. Use with caution and under the guidance of a specialist. ## Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is metabolized in the liver and excreted by the kidneys. However, caution is advised in patients with severe renal impairment. ## Contraindications * Known hypersensitivity to l-ornithine or l-aspartate. * Severe renal insufficiency (serum creatinine >3 mg/dL) may warrant caution due to the excretion of ornithine. ## Adverse Effects * Gastrointestinal disturbances: Nausea, vomiting, abdominal discomfort. * Rarely: Allergic reactions. ## Key Drug Interactions * No significant drug interactions have been consistently reported. ## Monitoring * Monitor for signs and symptoms of hepatic encephalopathy. * Electrolytes and renal function may be monitored periodically, especially in patients with pre-existing kidney disease. ## Clinical Pearls * The oral formulation is typically used for maintenance therapy once symptoms have improved with IV administration. * The effectiveness depends on the patient's ability to metabolize ammonia, which is impaired in liver disease. *** *Disclaimer: This information is intended for clinical pharmacy professionals and is not a substitute for the full prescribing information or a professional judgment. Always verify current prescribing information with the manufacturer and consult relevant clinical guidelines before making any treatment decisions.*